Human Genome Sciences (HGSI)

gplejeune (< 20) Submitted: 12/21/06 10:16 PM : Start Price: $12.67 HGSI Score: -35.09

I bought HGSI in 1999 for $70 because it was a Motley Fool “Rule Breaker”. Almost immediately it went to $110 because of a promising AIDS related drug. I kept it. What could go wrong? In March 2000 I lost my job. In April 2000 HGSI hit $40. Then it w...

Report this Post Replies: 2 | Reply | Permalink

Fergy2b (36.67) Submitted: 8/24/07 7:08 AM : Start Price: $8.72 HGSI Score: -8.11

Oversold recently

Report this Post Replies: 0 | Reply | Permalink

sailor175 (< 20) Submitted: 9/22/06 11:29 PM : Start Price: $11.59 HGSI Score: -36.71

insider buying.
very volatile and unpredictable.
it is on phase III for SLE drug a $300 MM market
has an arrangement with novartis for hepatitis C... big potential
signed a contract for $165 MM for anthrax drug delivering in 2009.....if approved

cou...

Report this Post Replies: 1 | Reply | Permalink

NetscribeHealthC (48.79) Submitted: 2/13/07 6:26 AM : Start Price: $11.64 HGSI Score: 28.98

Human Genome Sciences is harnessing the power of the human genome to develop innovative drugs. The company's research and development focuses on discovering and commercializing therapeutic proteins, antibodies and genes to advance clinical trials in ...

Report this Post Replies: 0 | Reply | Permalink

paden55 (89.39) Submitted: 10/21/06 6:11 PM : Start Price: $12.42 HGSI Score: -37.16

They have patented over 2,000 dna sequences already. Even if their products are not blockbusters, they will earn revenues on patents from other biotech companies. I like their approach and see them being the next pfeizer, etc.

Report this Post Replies: 0 | Reply | Permalink

ToddlesMD (59.60) Submitted: 9/14/06 11:44 PM : Start Price: $11.57 HGSI Score: -36.04

HGSI has a phenominal early stage pipeline of agents directed at very lucrative markets. While cash flow has been problematic for the company and profits are still years away, the stock is likely to take off (and stay there) on any positive news reg...

Report this Post Replies: 0 | Reply | Permalink

TMFBreakerBrian (99.68) Submitted: 5/16/08 6:28 AM : Start Price: $6.03 HGSI Score: -23.97

Good science. Multiple revenue sources. Bad lead drugs (compared to the competition)

Report this Post Replies: 0 | Reply | Permalink

volumewatcher (45.11) Submitted: 1/09/07 7:51 PM : Start Price: $12.31 HGSI Score: -34.08

Finally transitioning to a revenue generating company instead of a pure cash burner, with cash enough to last several years. Limited downside risk, with possible dramatic upside potential or possible acquisition target.

Report this Post Replies: 0 | Reply | Permalink

manvsmonkey (< 20) Submitted: 2/18/08 10:40 PM : Start Price: $6.87 HGSI Score: -6.50

hard to come out from so under S&P

Report this Post Replies: 0 | Reply | Permalink

allkindsofmoney (< 20) Submitted: 1/26/08 6:55 PM : Start Price: $5.87 HGSI Score: 20.77

hit alltime low of 6$ and three new drugs in final stages ...along with recent upgrades to buy on 1-24-08 by years expect this to double

Report this Post Replies: 0 | Reply | Permalink